Ro60, Y RNA binding proteinGenealiases: RORNP · SSA2 · TROVE2
Q-omics provides the consensus-scored RO60 profile across patient tissues and cancer cell-line models. RO60 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RO60 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, RO60 protein abundance shows 28,466 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where RO60 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RO60 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RO60 survival associations across molecular data types. RO60 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RO60 RNA expression–survival associations across cancer types. High RO60 expression shows unfavorable associations in ACC, KIRP, PAAD, BLCA and THCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RO60 RNA expression.
This table summarizes RO60 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RO60. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RO60 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The HNSC box plot shows higher RO60 RNA expression in tumor versus normal tissue (log2 FC = +0.821, t-test p < 0.001).
This table shows molecular features associated with RO60 in patient tissues and cancer cell lines. In patient samples, RO60 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RO60 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
